Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.
Burchardi
Christian
C
Medizinische Poliklinik der Ludwig-Maximilians-Universität, Pettenkoferstrasse 8a, Munich 80336, Germany.
Schlöndorff
Detlef
D
D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D011241:Prednisone